Molbio Diagnostics

Molbio Diagnostics has established itself as a pioneer in the point-of-care (POC) diagnostics space, focusing on bringing lab-grade accuracy to resource-limited settings. The company's core value proposition revolves around accessibility and speed, ensuring that critical diagnostic results are available within an hour, thereby reducing the time to treatment for patients.

The company's flagship product, Truenat, is a portable, battery-powered PCR testing platform. This technology allows for decentralized testing, moving the diagnostic process from centralized laboratories directly to the point of care. This business model addresses a critical gap in healthcare infrastructure, particularly in rural or underserved areas.

To maintain its competitive edge, Molbio operates through its wholly owned subsidiary, Bigtec Labs. This entity focuses on research and development, creating new diagnostic platforms and expanding the range of diseases that can be detected using the Truenat system. This R&D-led approach ensures a sustainable pipeline of products.

Operationally, the company has scaled its manufacturing capabilities to meet growing demand. It maintains significant infrastructure for its research and development facilities and a Center of Excellence. The company is also expanding its footprint with dedicated units in Goa and Visakhapatnam to increase production capacity.

The company is led by a diverse promoter group, including Chandrasekhar Bhaskaran Nair, Exxora Trading LLP, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram, and Sriram Natarajan. Their combined leadership has steered the company from a specialized R&D firm to a commercial diagnostic powerhouse.

The Molbio Diagnostics IPO is a Mainboard issue seeking to raise approximately ₹939.70 Crore. The issue is structured as a combination of a fresh issue of ₹200 Crore and an Offer for Sale (OFS) of approximately 91.66 Lakh shares, totaling ₹739.7 Crore. The price band is set between ₹768 and ₹807 per share, with a minimum retail lot size of 18 shares. The IPO is scheduled to be open from August 10 to August 12, 2026, with listing on the BSE and NSE on August 17, 2026.

Proceeds from the fresh issue are earmarked for strategic growth. Specifically, ₹118.08 Crore will be utilized for funding capital expenditure for the research and development facility and the Center of Excellence. An additional ₹79.04 Crore is allocated for the purchase of plant, machinery, and equipment for the company's units in Goa (Unit I and II) and Visakhapatnam.

Financially, Molbio has shown a strong growth trajectory. Revenue grew from ₹840.66 Crore in FY24 to ₹1,027.94 Crore in FY25, and further surged to ₹1,455.17 Crore in FY26. Profitability has followed a similar trend, with PAT increasing from ₹83.54 Crore in FY24 to ₹164.14 Crore in FY26, reflecting efficient scaling of operations.

In terms of valuation, the company reports a basic EPS of ₹14.77 for FY26. While the P/E ratio is not explicitly provided in the comparison, the company is benchmarked against peers like Poly Medicure, Dr. Lal Pathlabs, and Metropolis Healthcare. Its ROE of 15.59% and ROCE of 17.55% indicate healthy capital efficiency.

Investment strengths include the proprietary Truenat technology, a strong R&D focus via Bigtec Labs, and consistent top and bottom-line growth. However, the heavy reliance on the OFS component (approx 78.7% of the issue) may be viewed by some investors as a significant promoter exit, which could temper sentiment.

Overall, Molbio Diagnostics presents a compelling case for investors looking for exposure to the health-tech and diagnostic sector. The balance between high institutional demand and strong financial fundamentals suggests a positive outlook, though investors should weigh the high OFS proportion against the company's growth prospects.